Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C

Journal of Clinical Virology

Volumn 71, Issue , 2015, Pages 63-66

  Barreiro, Pablo ^a   Labarga, Pablo ^b   Fernandez Montero, José V ^c   Mendoza, Carmen de ^d   Benítez Gutiérrez, Laura ^d   Peña, José M ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b La Luz Clinic   (Spain)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Direct acting antivirals; Hepatitis C; HIV; Sofosbuvir; Viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS C; FEMALE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B CC GENE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; VIREMIA; BLOOD; CLINICAL TRIAL; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; PREVALENCE; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84941563178     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.08.001     Document Type: Article

References (24)

1. Medrano J., Neukam K., Rallón N., et al. Modelling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV. Clin. Infect. Dis. 2010, 51:1209-1216.
2. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virological response in hepatitis B and C. J. Hepatol. 2008, 49:634-651.
3. Poordad F., McCone J., Bacon B., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
4. Poordad F., Bronowicki J., Gordon S., et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-618.e5.
5. Osinusi A., Meissner E., Lee Y., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavourable treatment characteristics: a randomized clinical trial. JAMA 2013, 310:804-811.
6. arxiv:/(www.accessdata.fda.gov).
7. FDA Package insert for HARVONI.
8. Soriano V., Esposito I. Caution with new oral hepatitis C drugs. AIDS Rev. 2015, 17:121-122.
9. Hoofnagle J., Sherker A. Therapy for hepatitis C-the costs of success. N. Engl. J. Med. 2014, 370:1552-1553.
10. Grint D., Peters L., Reekie J., et al. Stability of HCV RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. 2013, 14:370-378.
11. McCaughan G., Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in HCV-infected recipients following liver transplantation. Liver Transpl. 2003, 9(Suppl):21-27.
12. Ziol M., Handra-Luca A., Kettaneh A., et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
13. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
14. de L., edinghen V., Douvin C., Kettaneh A., et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune. Defic. Syndr. 2006, 41:175-179.
15. Deeks E. Cobas AmpliPrep/Cobas Taqman HCV quantitative test version 2.0: an in vitro test for hepatitis C virus RNA quantification. Mol. Diagn. Ther. 2015, 19:1-7.
16. Kowdley K., Gordon S., Reddy K., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014, 370:1879-1888.
17. O'Brien T., Lang-Kuhs K., Pfeiffer R. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect. Dis. 2014, 1:ofu110.
18. Kohli A., Osinusi A., Sims Z., et al. Virological response after 6 week triple drug regimens for hepatitis C: a proof-of-concept phase 2 cohort study. Lancet 2015, 385:1107-1113.
19. Kwo P., Gitlin N., Nahass R., et al. A phase 3 randomized open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J. Hepatol. 2015, 62(Suppl. 2):270. [abstract LP14].
20. Wyles D., Ruane P., Sulkowski M., et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N. Engl. J. Med. 2015, (in press). 10.1056/NEJMoa1503153.
21. Ge D., Fellay J., Thompson A., et al. genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
22. Labarga P., Soriano V., Caruz A., et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-coinfected patients. AIDS 2011, 25:761-766.
23. Soriano V., Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:568-569.
24. Barreiro P., Fernandez-Montero J.V., de Mendoza C., Labarga P., Soriano V. Towards hepatitis C eradication from the HIV-infected population. Antivir. Res. 2014, 105:1-7.